Form 8-K - Current report:
SEC Accession No. 0001628280-24-045054
Filing Date
2024-11-04
Accepted
2024-11-04 17:15:55
Documents
13
Period of Report
2024-11-04
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20241104.htm   iXBRL 8-K 28443
  Complete submission text file 0001628280-24-045054.txt   153879

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20241104.xsd EX-101.SCH 1894
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20241104_lab.xml EX-101.LAB 21900
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20241104_pre.xml EX-101.PRE 12611
15 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20241104_htm.xml XML 2828
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 241424720
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)